Mesothelioma News and Research

RSS

Mesothelioma is a form of cancer that is almost always caused by previous exposure to asbestos. In this disease, malignant cells develop in the mesothelium, a protective lining that covers most of the body's internal organs. Most people who develop mesothelioma have worked on jobs where they inhaled asbestos particles, or have been exposed to high levels of asbestos fibers.

ONCOblot test shows promise in early detection of malignant mesothelioma

MorNuCo Laboratories of West Lafayette, Indiana, and their ONCOblot Test recently completed a retrospective clinical trial focusing on the early detection of malignant mesothelioma, with the exciting results that the ONCOblot test detected a molecular marker that is indicative of the presence of mesothelioma, 4-10 years in advance of clinical symptoms appearing.

5 Feb 2016

Bevacizumab extends survival of pleural mesothelioma patients

Patients with unresectable, malignant pleural mesothelioma derive a significant survival benefit from the addition of bevacizumab to standard treatment according to phase III trial findings published in The Lancet.

19 Jan 2016

Four unrelated families share identical BAP1 mutation that causes several cancers

University of Hawai'i Cancer Center researchers discovered members of four families, apparently unrelated and living in different states across the US, shared the identical mutation of a gene called BAP1 that causes mesothelioma, melanoma, renal carcinoma and other cancers.

23 Dec 2015

Lilly, Merck expand oncology clinical trial collaboration

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly's ALIMTA (pemetrexed for injection) and Merck's KEYTRUDA (pembrolizumab) in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC).

19 Nov 2015

Research finding offers hope for more powerful aspirin-like drugs

Researchers have found that salicylic acid targets the activities of HMGB1, an inflammatory protein associated with a wide variety of diseases, offering hope that more powerful aspirin-like drugs may be developed.

11 Oct 2015

VA Hospital performs first successful heated chemotherapy bath on a patient with mesothelioma

Nationalmesotheliomaclaims.com, a comprehensive website that provides people with mesothelioma and their families with in-depth information and free resources about the disease, is excited to report that a VA Hospital in Roxbury, MA has just performed the first successful heated chemotherapy bath.

30 Sep 2015

$Atezolizumab may change treatment strategies for refractory lung cancer patients$

Atezolizumab may change treatment strategies for refractory lung cancer patients

Atezolizumab is set to substantially change treatment strategies for patients with refractory lung cancer, according to Dr Martin Reck, Chief Oncology Physician in the Department of Thoracic Oncology, Hospital Grosshansdorf, Germany. Reck's comments came as the results from the POPLAR and BIRCH studies showing the first results of efficacy with atezolizumab across lines were presented at the European Cancer Congress 2015 (ECC 2015) in Vienna, Austria.

28 Sep 2015

Mesothelioma.us releases some critical information about how to avoid mesothelioma

Mesothelioma.us, a free online resource that provides people with mesothelioma and their families with educational articles and other information about the disease, has just released some critical information about how to beat mesothelioma.

19 Sep 2015

Mesothelioma website posts encouraging news about mesothelioma

Mesothelioma.us, a free online resource filled with helpful information for people who have been diagnosed with mesothelioma, is now reporting that mesothelioma is more beatable than previously believed.

10 Sep 2015

New statistical model may help predict patients more likely to benefit from surgical treatment for mesothelioma

A new statistical model may help predict which patients are most likely to receive life-extending benefits from surgical treatment for malignant pleural mesothelioma (MPM), according to an article in the September 2015 issue of the Annals of Thoracic Surgery.

9 Sep 2015

Penns' Abramson Cancer Center rated as 'exceptional' by NCI

The University of Pennsylvania's Abramson Cancer Center (ACC) has received an "exceptional" rating by the National Cancer Institute during an extensive peer-review process for its five-year competitive research support grant. The rating is the highest possible for an NCI cancer center.

9 Sep 2015

AstraZeneca presents lung cancer research data at WCLC 2015

Data will be reported from across AstraZeneca’s industry-leading lung cancer portfolio at the World Conference on Lung Cancer 2015, beginning this weekend in Denver, Colorado.

8 Sep 2015

Mesothelioma website provides three new tips to combat disease

Mesothelioma.us, a free online resource that features comprehensive resources for people who have been diagnosed with mesothelioma, has just unveiled three new tips for beating the disease.

4 Sep 2015

New statistical model may help predict patients most likely to benefits from surgical treatment for mesothelioma

1 Sep 2015

New NCCN Guidelines for Patients and NCCN Quick Guide for Kidney Cancer published

Kidney Cancer is among the 10 most diagnosed cancers in both men and women in the United States, and it is estimated that more than 60,000 new cases of kidney cancer will be diagnosed in 2015.

27 Aug 2015

MTG Biotherapeutics' MTG-201 granted FDA Orphan Drug Designation for malignant mesothelioma treatment

MTG Biotherapeutics, an immuno-oncology company developing novel therapeutics for the treatment of cancer, today announced that the US Food and Drug Administration has granted Orphan Drug Designation for MTG-201, an advanced biologic therapy targeting Dickkopf-3 gene defects in various cancers, for the treatment of malignant mesothelioma.

23 Aug 2015

EnGeneIC begins Phase 1 Tailored-EDV trial for advanced solid tumor

EnGeneIC Ltd., an emerging biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of cancer therapeutics, today announced that the first patient has been dosed in its Phase 1 Tailored-EDV trial. The trial is being conducted at the Northern Cancer Institute in Sydney, Australia.

19 Aug 2015

Secondhand exposure to asbestos could lead to mesothelioma

Mesothelioma.us, a free online resource that provides people with mesothelioma and their loved ones with in-depth and educational articles, information packets and more about the disease, has just posted a new article that discusses secondhand exposure to asbestos.

7 Aug 2015

Mesothelioma.us posts exhaustive list of companies involved with asbestos manufacturing

Mesothelioma.us, an online resource filled with educational articles for people who have been diagnosed with mesothelioma, has just posted an exhaustive list of the hundreds of companies that have manufactured asbestos.

6 Aug 2015

Clinical data on TomoTherapy System presented at AAPM 2015

Accuray Incorporated announced today that studies on the clinical use of the TomoTherapy System continue to demonstrate its mainstream use and the benefits of its gold-standard treatment planning and delivery capabilities. More than 30 studies were presented during poster or oral sessions at the 57th Annual Meeting of the American Association of Physicists in Medicine held in Anaheim, California July 12 – July 16, 2015.

14 Jul 2015